Evidence map›Paper›PMID 35245888›Full record

ArticleOral oncology2022

A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers.

Robert M Brody, David Shimunov, Roger B Cohen, Alexander Lin, John N Lukens, Lee Hartner, Charu Aggarwal, Umamaheswar Duvvuri, Kathleen T Montone, Jalal B Jalaly and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oral oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Oncologic Outcomes of Transoral Robotic Surgery in HPV-Associated OPSCC: A Systematic Review and Meta-Analysis.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026
    Pooled it
  2. Review
  3. Surveillance after treatment for head and neck cancer.Current opinion in otolaryngology & head and neck surgery · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Robert M BrodyDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States; Department of Biostatistics Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Robert.Brody2@pennmedicine.upenn.edu.
David ShimunovDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: David.Shimunov@pennmedicine.upenn.edu.
Roger B CohenDepartment of Internal Medicine, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Roger.Cohen@pennmedicine.upenn.edu.
Alexander LinDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Alexander.Lin2@pennmedicine.upenn.edu.
John N LukensDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: John.Lukens@pennmedicine.upenn.edu.
Lee HartnerDepartment of Internal Medicine, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: lee.hartner@pennmedicine.upenn.edu.
Charu AggarwalDepartment of Internal Medicine, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: charu.aggarwal@pennmedicine.upenn.edu.
Umamaheswar DuvvuriDepartment of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, United States. Electronic address: duvvuriu@upmc.edu.
Kathleen T MontoneDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: kathleen.montone@pennmedicine.upenn.edu.
Jalal B JalalyDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: jalal.jalaly@pennmedicine.upenn.edu.
Virginia A LiVolsiDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: linus@pennmedicine.upenn.edu.
Ryan M CareyDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Ryan.Carey@pennmedicine.upenn.edu.
Rabie M ShantiDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: rabie.shanti@pennmedicine.upenn.edu.
Karthik RajasekaranDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Karthik.Rajasekaran@pennmedicine.upenn.edu.
Ara A ChalianDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Ara.Chalian@pennmedicine.upenn.edu.
Christopher H RassekhDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Christopher.Rassekh@pennmedicine.upenn.edu.
Steven B CannadyDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Steven.Cannady@pennmedicine.upenn.edu.
Jason G NewmanDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Jason.Newman@pennmedicine.upenn.edu.
Bert W O'MalleyDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: bert.omalley@umm.edu.
Gregory S WeinsteinDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Gregory.Weinstein@uphs.upenn.edu.
Phyllis A GimottyDepartment of Biostatistics Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: pgimotty@pennmedicine.upenn.edu.
Devraj BasuDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: devraj.basu@uphs.upenn.edu.

Funding

JARID1B-mediated epigenetic regulation of oncogenic signals in oral cancerR01DE027185 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI BASU, DEVRAJ · 2018 to 2021
$1.5M
NIDCR NIH HHS R01 DE027185
6 · The paper itself

Abstract

objectivesIncreasing use of transoral robotic surgery (TORS) is likely to impact outcomes for HPV+ oropharyngeal squamous cell carcinomas (OPSCCs). We aimed to describe oncologic outcomes for a large HPV+ OPSCC cohort after TORS and develop a risk prediction model for recurrence under this treatment paradigm. MATERIALS AND

methods634 HPV+ OPSCC patients receiving TORS-based therapy at a single institution were reviewed retrospectively to describe survival across the entire cohort and for patients suffering recurrence. Risks for distant metastatic recurrence (DMR) and locoregional recurrence (LRR) were modeled using multivariate logistic regression analyses of case-control sub-cohorts.

results5-year overall and recurrence-free survival were 91.2% and 86.1%, respectively. 5-year overall survival was 52.5% following DMR and 83.3% after isolated LRR (P = .01). In case-control analyses, positive surgical margins were associated with DMR (adjusted OR 5.8, CI 2.1-16.0, P = .001), but not isolated LRR, and increased DMR risk 4.2 fold in patients with early clinical stage disease. By contrast, LRR was associated with not receiving recommended adjuvant therapy (OR 13.4, CI 6.3-28.5, P < .001).

conclusionsThis study sets a benchmark for oncologic outcomes from HPV+ OPSCC after TORS-based therapy. Under this treatment paradigm, margins are relevant for assessing lethal recurrence risk during clinical trial design and post-treatment surveillance.

Indexed as

Head and Neck NeoplasmsOropharyngeal NeoplasmsPapillomavirus InfectionsRobotic Surgical ProceduresBenchmarkingHumansNeoplasm Recurrence, LocalRetrospective StudiesDistant metastasisHead and Neck cancerHead and neck squamous cell carcinomaHPVOropharyngeal cancerTORS

Identifiers

PMID35245888
PMCPMC9288202

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.